TrialInvestigational new drugs2020

A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer.

Lipika Goyal et al.PubMed ↗Publisher ↗

No numbers read from the abstract.